given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4) receptor blockers. The medication is not available in a biosimilar version.
For an in-depth look and details about the drug’s uses, see this Dupixent overview article. Dupixent pen and Dupixent syringe are used to give Dupixent doses by subcutaneous injection.
Global healthcare company Sanofi and Regeneron Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injection to patients suffering from ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
Hosted on MSN1mon
He paid $38,398 for a single shot of a very old cancer drugDrugs like Dupixent for eczema fall into this category ... If you’re about to get an injection, infusion, or procedure done in a hospital system, ask ahead of time for an estimate of what ...
These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...
Sanofi has upped its revenue forecasts for the year on the back of strong second quarter results from its new eczema and asthma injection Dupixent and ... So far the drug has been launched in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback